44 results about "Muscle disorder" patented technology

Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission which are useful in treating anal fissure and other wounds and muscle disorders are provided. Also provided are methods of treating wounds and muscle disorders by administering the composition of the invention to a muscle or in the vicinity of a muscle either topically or by injection.

Methods and systems are directed to evaluating a pathological condition and involve acquiring muscle movement signals, such as electromyogram (EMG) or accelerometer signals, and detecting the presence of the pathological condition. Methods and systems also provide for detecting sleep-related involuntary muscle disorders and non sleep-related involuntary muscle disorders using muscle movement signals. Drug therapy, transcutaneous electric nerve stimulation therapy, or other therapy may be delivered to treat a detected or diagnosed involuntary muscle disorder.

Various methods and compositions for treating age-associated conditions and other medical conditions, such as muscle diseases, type 2 diabetes, and / or obesity are described. Methods of enhancing cellular uptake of NMN and stimulating NAD+ production are further described. Various mammalian cells and mammalian cell lines are described including those comprising a cDNA encoding a Slcl2a8 protein. Gene therapy vectors comprising a nucleic acid encoding Slcl2a8 and non- human animals comprising an inactivating mutation in a Slcl2a8 gene are also disclosed. Also described are methods for screeninga candidate compound to identify compounds that promote NMN transport.

The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, therebyenabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamentalprevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.

The present invention relates to a composition for preventing or treating a muscle disorder, which includes a chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1α, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance. In addition, the present invention is a natural substance and may be safely used without a side effect, and therefore may be used as a medication, food or a cosmetic.

The present invention relates to compositions comprising compounds for use in treating, ameliorating and / or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and / or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.

The present invention relates to a composition for promoting myogenesis, containing, as an active ingredient, a processed ginseng extract in which a trace amount of a ginsenoside ingredient is increased. It has been ascertained that the processed ginseng extract promotes the differentiation of myoblasts into muscle and inhibits muscle atrophy caused by myostatin, which is a myogenesis inhibitory factor, and thus it is expected that a composition for preventing or treating muscle disorder-related diseases, having excellent effects, can be developed.

The present invention relates to applications of an immune system-released activating agent (ISRAA) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. The ISRAA polypeptide is for use in a method of treatment of patients with immunodeficiency, immunosuppression or autoimmune disease; cancer; neurologic diseases and disorders; or muscular diseases and disorders.

The invention relates to a method for high throughput screening compounds by using a plurality of automated cell based assays assessing skeletal muscle cells contractility, morphology, and metabolism, in order to predict the efficacy of said compound on a panel of applications linked with muscle physiological and pathophysiological processes, comprising: (i) providing an in vitro culture of myotubes, wherein the in vitro myotubes culture is obtained by the following method: providing a cell culture device allowing the culture of myoblasts or myotubes, depositing said cells from a human donor or human group of donors, in good health or affected by a muscle related disorder, from primary cells, a cell line, an isogenic cell line or differentiated stem cells recapitulating a muscle disorder, on said culture device by using a method allowing the spatial control of cell culture, culturing said cells during a determined incubation time so as to promote a spatially controlled myotube culture; (ii) adding at least one compound to said culture; (iii) after a determined incubation time of the myotubes with said compound, carrying out structural and / or functional readouts of the myotubes to determine the effect of said compound on the myotubes; and (iv) based on said determined effect, predicting the ability of said compound to improve or alter healthy muscle features, or to treat, rescue, or cure muscle disorders, said features or said disorders being linked with muscle contraction, muscle morphology or muscle metabolism.

The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may “crack” a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro-drug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or / and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases Alzheimer's diseases, Parkinson's diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon-rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers.

A unit has been designed to be applied within the area of physiotherapy and is applicable to both medical and athletic therapeutic programs to provide correction of functional states of the spine and the nervous system to eliminate nervous overloads, fatigue, and stress. Moreover, the unit corrects spinal disorders, paravertebral muscular disorders and can be used as a part of mobilizing procedures to act on biologically active body points, and as a part of therapeutic procedures to relieve the spine.